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ABSTRACT
Objective: To calculate the excess mortality, length of
stay, and costs attributable to serious fungal infections in
hospitalized elderly patients with selected cancers.
Methods: This study involved a retrospective cohort
analysis using linked data from the Surveillance, Epide-
miology and End Results Program of the National Cancer
Institute (SEER) and Medicare claims data. Study cohorts
included patients aged 65 years and older who newly
received a diagnosis of a selected cancer (acute myeloid
leukemia [AML] or squamous cell carcinoma of the head
and neck [SCCHN]) in a SEER registry between 1991 and
1996 and who had a subsequent diagnosis of a serious
fungal infection during an inpatient hospitalization, and
hospitalized controls without a fungal infection matched
1:1 by age, geographic region, receipt of recent chemo-
therapy, concomitant bacterial infection, timing of the
index hospitalization, and cancer stage at diagnosis (for
SCCHN patients only).
Results: Eighty AML patients and 52 SCCHN patients
experienced a serious fungal infection involving hospital-
ization. Relative to matched controls, SCCHN patients
with fungal infections had signiﬁcantly higher all-cause
mortality (40% vs. 14%, P = 0.002), while mortality rates
did not differ between AML cohorts. Patients with fungal
infections had signiﬁcantly longer index hospitalizations
regardless of cancer type (mean: 30 days vs. 19 days for
AML patients; 20 days vs. 9 days for SCCHN patients),
and correspondingly higher Medicare payments (mean ±
SD: $34,268 ± $31,811 vs. $21,416 ± $22,449 among
AML patients, P < 0.0001; $25,942 ± $29,122 vs.
$10,131 ± $10,686 among SCCHN patients, P < 0.0001).
Conclusions: Efforts to prevent these infections and/or
initiate early treatment may yield both clinical and eco-
nomic beneﬁts.
Keywords: costs, economics, fungal infections, mortality,
outcomes.
Introduction
Since the 1980s, there has been an explosive rise in
the rate of fungal infections in hospitalized patients
[1–4]. Fungi now rank as the fourth most common
pathogen among nosocomial bloodstream infec-
tions, increasing ﬁvefold over the past two decades,
and accounting for about 5% to 15% of hospital-
acquired blood infections [3,5–8]. Most serious
fungal infections are caused by Candida and
Aspergillus, although infections also may be caused
by Cryptococcus, Histoplasma, and other fungi.
Patients in intensive care units (ICU) and those who
are immunocompromised because of surgery, chem-
otherapy, or diseases of the immune system are at an
increased risk of contracting serious fungal infec-
tions [7,9], with elderly patients in these situations
facing even higher risk and poorer associated out-
comes [10–12].
Cancer patients, because of their immunocom-
promised status, treatment with chemotherapy,
periods of neutropenia, central venous catheteriza-
tion, and in some cases, receipt of bone marrow
transplants, are at particularly high risk of develop-
ing serious fungal infections [7,9,13–15]. One study
noted that 25% of the patients with malignancy
have an invasive fungal infection that is often only
diagnosed at autopsy [16].
While several studies have evaluated the epide-
miological trends and treatment patterns associated
with serious fungal infections [1,2,4,7–9,13–15,17],
few have assessed the economic impact of these
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infections, especially among cancer patients [13]. In
particular, data on the costs of fungal infections
among elderly cancer patients are lacking. Most
existing studies have examined excess costs attrib-
utable to fungal infections across broad patient
populations (grouping cancer patients with other
risk groups for infection) and/or among patients in
single institutions [3,5,6,18–21].
In this study, we focus on elderly patients with
cancer, evaluating two types—a hematologic malig-
nancy (acute myeloid leukemia [AML]) and a solid
tumor (squamous cell carcinoma of the head and
neck [SCCHN])—that have been the subject of
prior economic research by the study authors
[22,23]. We use linked data from the Surveillance,
Epidemiology and End Results Program of the
National Cancer Institute (SEER) and from Medi-
care claims to address the following questions of
interest: 1) How do fungal infections among elderly
cancer patients impact mortality? and 2) What are
the excess lengths of stay and costs associated with
such infections? To address these questions, we
undertook a nested case-control analysis within a
retrospective cohort study.
Methods
Data Source
The analysis used a linking of clinical data from
SEER cancer registries and Medicare claims. The
SEER-Medicare database was created through col-
laboration by the National Cancer Institute, the
SEER registries, and the Health Care Financing
Administration (HCFA, now known as the Centers
for Medicare and Medicaid Services, CMS). SEER is
an epidemiologic surveillance system consisting of
11 population-based tumor registries designed to
track cancer incidence and survival in the United
States. The registries routinely collect information
on newly diagnosed cancer patients in geographi-
cally deﬁned areas that represent approximately
14% of the US population. The registries ascertain
all newly diagnosed cancer cases from multiple
reporting sources [24].
The linked information for this study included a
SEER data ﬁle as well as Medicare claims ﬁles cov-
ering the period from 1991 to 1998. The SEER ﬁle
includes demographics (e.g., age, sex, race, date of
death), SEER diagnostic information for up to 10
different incident cancer cases for each person,
including date of cancer diagnosis, cancer site/type
(e.g., oral cavity, pharynx), cancer stage at diagnosis
for solid tumors (i.e., in situ, local, regional, distant,
unstaged), and indicators for surgery and radiation
in the 4 months after diagnosis. The Medicare
claims ﬁles include enrollment data (e.g., HMO
enrollment, months of Part A and/or Part B eligibil-
ity) and details on inpatient hospital, outpatient,
physician, home health, hospice, and skilled nursing
facility (SNF) utilization. Claims details include
dates of service, types of service, International Clas-
siﬁcation of Diseases (Ninth Revision) Clinical
Modiﬁcation (sixth edition) (ICD-9-CM) diagnosis
codes (up to 10), ICD-9-CM procedure codes (up to
10), diagnostic related group (DRG) (1 in inpatient
ﬁle), HCFA’s Common Procedure Coding System
(HCPCS) codes (1 in outpatient and physician ﬁles),
and Medicare payment amounts. Combining the
SEER and Medicare data provided us with informa-
tion on both initial cancer diagnosis and later can-
cer treatment, as well as the downstream medical
care for cancer patients.
Cohort Selection
Two fungal infection cohorts, one for AML and one
for SCCHN, and two mutually exclusive compari-
son cohorts, one for each cancer type, were selected
for inclusion in the analysis. Patients were followed
up for 30 days after discharge from their index hos-
pitalization (i.e., the hospitalization selected for
analysis) or until death, whichever occurred ﬁrst. To
be included in the study, patients were required to
be at least 65 years old, have a diagnosis of AML or
SCCHN as their ﬁrst cancer between January 1,
1991 and December 1996, and have been hospital-
ized at least once after diagnosis. Cancers were
deﬁned according to the site recode variable in the
SEER registry data (i.e., for AML, site recode value
77;  for  SCCHN,  including  cancers  of  the  lip,
tongue, salivary gland, ﬂoor of mouth, gum,
nasopharynx, tonsil, oropharynx, and hypophar-
ynx, and cancers of the nasal cavity and larynx, site
recode values 1–10, 37, and 38).
Speciﬁc cohorts were selected as follows.
Fungal infection cohorts. Cancer patients who met
the study inclusion criteria were assigned to the fun-
gal infection cohorts, one for AML and one for
SCCHN, if they received at least one diagnosis of a
serious fungal infection (see Appendix for a full list
of ICD-9-CM diagnosis codes used to deﬁne serious
fungal infections) during one or more hospital
admissions after their cancer diagnosis. Each
patient’s earliest such hospitalization in the study
period was designated as the “index hospitaliza-
tion” and selected for analysis. Patients enrolled in
an HMO or ineligible for Part A or Part B Medicare
beneﬁts at any time from the index date through
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30 days post hospital discharge were excluded from
the analysis, as complete claims may not have been
available for them.
Comparison cohorts. Matched comparison cohorts
(one for AML and one for SCCHN) were created
from the pool of remaining cancer patients who met
the study inclusion criteria. One patient with the
same cancer type was randomly selected if he or she
matched a fungal infection patient on: 1) age group
(55–64, 65–74, 75–84, 85+); 2) geographic region;
3) cancer stage at diagnosis (in situ, local, regional,
distant) for SCCHN patients only; and 4) presence
of a hospitalization with characteristics that
matched the fungal infection patient’s index hospi-
talization. These hospitalization characteristics
included presence or absence of chemotherapy in
the prior 30 days (identiﬁed by the presence of ICD-
9-CM diagnosis code v58.1, ICD-9-CM procedure
code 99.25, or DRG code 410 or 492), presence or
absence of concomitant bacterial infection (identi-
ﬁed by ICD-9-CM diagnosis codes 36.xx, 37.xx,
38.xx, 40.xx, 41.xx, 482.xx, 485.xx, or 486.xx),
and whether the hospitalization was the ﬁrst or a
subsequent hospitalization after cancer diagnosis.
Patients enrolled in HMOs and those not eligible
for Part A or Part B Medicare beneﬁts during the
study period were not eligible for inclusion in the
comparison groups.
Study Measures
Outcomes were evaluated during the index hospi-
talization and over 30 days post discharge. Index
hospitalization outcome measures included mortal-
ity, length of hospital stay, intensive care utilization
(based on the intensive care use ﬂag in the Medicare
claims ﬁles), ventilator use (based on ICD-9-CM
procedure codes 93.9, 96.7, 96.70–96.72, and ICD-
9-CM diagnosis code v46.1), and total charges and
Medicare payments for the hospitalization. All
charges and payments were converted to 1998
dollars using the medical care component of the
Consumer Price Index. Postdischarge outcome
measures, for patients with a live discharge from
their index hospitalization, included mortality and
rehospitalization.
Statistical Analyses
Study cohorts were described in terms of patient
characteristics, including matching variables (age,
geographic region, cancer stage, receipt of prior
chemotherapy, concomitant bacterial infection,
whether or not the index hospitalization was the
ﬁrst or a subsequent admission after the cancer
diagnosis), other demographics (sex, race, residence
in a metropolitan county), and comorbidity. The
latter was deﬁned over the entire study period using
the Deyo adaptation of the Charlson comorbidity
index. This index was created by deﬁning binary
variables indicating the presence of ICD-9-CM
codes representing each of 17 comorbid conditions,
and applying standard weights to create a single
comorbidity index [25]. Cancer-related comorbidi-
ties were excluded from the index (malignancy,
solid tumors, and for SCCHN only, chronic pulmo-
nary disease).
To account for the matched study design, paired-
sample statistical techniques were used to evaluate
the signiﬁcance of differences in unmatched patient
characteristics and the primary outcomes measures.
McNemar’s test was used to evaluate differences in
dichotomous variables (i.e., sex, race, metropolitan
residence, mortality, ICU utilization, and ventilator
use), while the Wilcoxon signed rank test was used
to assess differences in continuous variables (i.e.,
age, comorbidity score, length of stay, days in ICU,
total charges and Medicare payments). Differences
were compared between the fungal infection and
comparison cohorts for each type of cancer sepa-
rately. In addition, multivariate analyses based on
analysis of variance techniques were undertaken to
estimate the impact of unmatched characteristics
(i.e., sex, race, comorbidity score) on key study
outcomes. These included multiple linear regres-
sions for continuous measures (e.g., total charges
and Medicare payments), and logistic regressions
for in-hospital mortality. SAS Version 8.0 (SAS
Institute Inc., Cary, NC, USA) was used in all
analyses.
Results
Patient Characteristics
A total of 2306 AML patients were eligible for
inclusion in the study. From this pool, 80 patients,
who had received a diagnosis of a serious fungal
infection while hospitalized, were included in the
AML fungal infection cohort. A 1:1 matched cohort
of 80 AML patients with no serious fungal infec-
tions was designated as the AML comparison
group. Similarly, from a total of 14,284 SCCHN
patients who met the study inclusion criteria, 52
patients with a diagnosis of a serious fungal infec-
tion during hospitalization were included in the
SCCHN fungal infection cohort, and 52 matched
SCCHN patients with no serious fungal infections
constituted the SCCHN comparison group. Among
fungal infection patients with either cancer, the
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most frequent type of infection was Candidiasis,
followed by Aspergillosis (Table 1).
Study cohorts were similar in terms of baseline
and demographic characteristics (see Table 2). Aver-
age age among patients in all study cohorts was
approximately 73 years, with approximately 85%
of patients white, and more than 85% of patients
residing in metropolitan counties. Patients in the
SCCHN cohorts had slightly higher Charlson
comorbidity scores than the AML patients (0.9
among SCCHN patients in both cohorts vs. 0.6–0.8
among AML patients), but more AML patients
were treated with chemotherapy in the 30 days
before index (58% vs. 12%). AML patients also
were less likely to have been hospitalized before
their index hospitalization (56% vs. 79%), and less
likely to have a concomitant bacterial infection
(40% vs. 52%).
Study Outcomes
Relative to the matched comparison group without
fungal infections, SCCHN patients with fungal
infections had a signiﬁcantly higher rate of death
during the index hospitalization (40% vs. 14%,
P = 0.002; Table 3). Consistent with this poorer
outcome, ventilator use and the duration of stay in
ICU were both signiﬁcantly higher for SCCHN
patients with fungal infections versus matched con-
trols. The mean total length of hospitalization also
was signiﬁcantly longer (19.7 days vs. 8.8 days for
controls; P < 0.001).
The main impact of fungal infections among
AML patients was to signiﬁcantly lengthen the
Table 2 Characteristics among patients with selected cancers (AML and SCCHN) who developed fungal infections and control
patients
Characteristic
AML patients SCCHN patients
Cases
(N = 80)
Controls
(N = 80) P value
Cases
(N = 52)
Controls
(N = 52) P value
Age*
Mean (SD) 72.8 (5.4) 73.0 (4.8) 73.0 (5.8) 73.6 (5.1) —
Median 72.0 73.0 72.5 73.5
Male, n (%) 58 (72.5) 43 (53.8) 0.0143 28 (53.8) 32 (61.5) 0.43
White, n (%) 66 (82.5) 68 (85.0) 0.6692 43 (82.7) 45 (86.5) 0.59
Location of  patient’s residence, n (%) 0.11
Metropolitan county 69 (86.3) 70 (87.5) 0.8155 44 (84.6) 49 (94.2)
Nonmetropolitan county 11 (13.8) 10 (12.5) 8 (15.4) 3 (5.8)
Geographic region,* n (%) —
Northeast 11 (13.8) 11 (13.8) 6 (11.5) 6 (11.5)
South 4 (5.0) 4 (5.0) 6 (11.5) 6 (11.5)
Midwest 22 (27.5) 22 (27.5) 10 (19.2) 10 (19.2)
West 43 (53.8) 43 (53.8) 30 (57.7) 30 (57.7)
Cancer stage,* n (%): —
In situ NA NA 1 (1.9) 1 (1.9)
Localized NA NA 15 (28.8) 15 (28.8)
Regional NA NA 16 (30.8) 16 (30.8)
Distant NA NA 6 (11.5) 6 (11.5)
Unstaged NA NA 14 (26.9) 14 (26.9)
Charlson comorbidity index†
Mean (SD) 0.6 (0.8) 0.8 (0.9) 0.1244 0.9 (1.1) 0.9 (1.3) 0.86
Median 0.0 1.0 0.5 0.5
Treated with chemotherapy within 30 days prior
to index,* n (%)
46 (57.5) 46 (57.5) 6 (11.5) 6 (11.5) —
Index stay was ﬁrst admission after cancer 
diagnosis,* n (%)
45 (56.3) 45 (56.3) 41 (78.8) 41 (78.8) —
Concomitant bacterial infection,* n (%) 32 (40.0) 32 (40.0) 27 (51.9) 27 (51.9) —
*Matching variable; differences between groups not tested.
†Charlson index for AML patients calculated excluding cancer-related comorbidities (malignancy and solid tumor); Charlson index for SCCHN patients calculated
excluding cancer-related comorbidities and chronic obstructive pulmonary disease.
Source: SEER-Medicare Data, 1991–98.
Percents may not add to 100 because of  rounding.
NA, not applicable.
Table 1 Fungal infections diagnosed in SCCHN and AML
patients during index hospitalization
Type of  fungal infection
AML
patients
(N = 80)
SCCHN
patients 
(N = 52)
Candidiasis of  lung 19 (23.8%) 22 (42.3%)
Disseminated candidiasis 26 (32.5%) 17 (32.7%)
Candidal enteritis 2 (2.5%) 1 (1.9%)
Histoplasmosis pneumonia 0 (0.0%) 1 (1.9%)
Histoplasma capsulatum pneumonia 1 (1.3%) 0 (0.0%)
Aspergillosis 29 (36.3%) 10 (19.2%)
Cryptococcosis 2 (2.5%) 1 (1.9%)
Zygomycosis 1 (1.3%) 0 (0.0%)
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duration  of  hospital  stay,  both  in  ICU  (2.7 days
vs. 1.5 days for controls; P < 0.0394) and overall
(30.3 days vs. 19.0 days; P < 0.0001; Table 3). As
with total length of stay, the cost impact of fungal
infections was similar for the SCCHN and AML
groups (Table 3), with Medicare payments $12,000
to $15,000 higher, and total charges over $50,000
higher, on average, for the fungal infection cohorts
versus the matched comparison cohorts. Consider-
ing only pairs of patients in which both were dis-
charged alive from the index hospitalization,
outcomes associated with the index hospitalization
were similar for the two cancer types, approxi-
mately 11 excess hospital days attributable to fun-
gal infections, with average excess Medicare
payments of approximately $15,000.
Findings from multivariate analyses that control-
led for unmatched variables were nearly identical to
the ﬁndings reported above (Table 4). These results
indicated that the excess length of stay, Medicare
costs, and total charges were 11 days, $15,966, and
$53,682, respectively, for the SCCHN fungal infec-
tion cohort, and 10 days, $10,479, and $49,474,
respectively, for the AML fungal infection cohort.
This is not surprising since most of the unmatched
variables were not signiﬁcantly different between
the fungal infection and control groups (Table 2).
Among patients who were discharged alive after
the index hospitalization, the presence of a serious
fungal infection did not increase the risk of mortal-
ity or rehospitalization over the subsequent 30 days
(see Table 5).
Discussion
In this retrospective analysis using data from the
linked SEER-Medicare database, we found that eld-
erly patients with AML or SCCHN who received a
diagnosis in a hospital of a serious fungal infection
had signiﬁcantly longer lengths of hospital stay and
higher costs compared with similar cancer patients
without such infections. In addition, among
patients with SCCHN, the presence of fungal infec-
tions was associated with increased mortality. Our
ﬁndings are similar to those from several other stud-
ies with more heterogeneous patient populations,
which also indicate a large clinical and economic
burden associated with serious fungal infections
[3,5,6,18,19,21]. For example, the excess mortality
we observed among SCCHN patients with fungal
infections (i.e., 27%) is consistent with literature,
suggesting a crude attributable mortality rate in the
range of 20% to 40%, depending on the speciﬁc
population studied [5,6,18,19]. It is possible that
we did not observe excess mortality among AML
patients because these patients have very short sur-
vival regardless of the presence of fungal infection
[22]. We found an excess length of hospital stay of
about 11 days, which is in the range (10–20 days)
of that found in other studies [5,6,18,19], although
our estimate is at the lower end. This is not unex-
pected since the data we used are more recent, and
treatment patterns may now reﬂect shorter hospital
stays. The excess Medicare hospital expenditures
we observed ($12,000–$15,000, on average) also
Table 3 Outcomes during index hospitalization among patients with selected cancers (AML and SCCHN) who developed fungal
infections and control patients
Characteristic
AML patients SCCHN patients
Cases
(N = 80)
Controls
(N = 80) P value
Cases
(N = 52)
Controls
(N = 52) P value
Mortality, n (%) 29 (36.3) 32 (40.0) 0.6264 21 (40.4) 7 (13.5) 0.0021
Length of  hospitalization
Mean (SD) 30.3 (19.2) 19.0 (16.5) 0.0001 19.7 (14.2) 8.8 (6.8) <0.0001
Median 26.5 14.5 15.0 7.0
IQ range 17–41 6–28 9–24 3–14
Utilization of  ICU, n (%) 25 (31.3) 18 (22.5) 0.2133 23 (44.2) 14 (26.9) 0.0666
Number of  days in ICU
Mean (SD) 2.7 (7.0) 1.5 (5.7) 0.0394 4.8 (9.6) 1.0 (3.2) 0.0065
Median 0.0 0.0 0.0 0.0
IQ range 0–2 0–0 0–4 0–1
Utilization of  ventilator, n (%) 5 (6.3) 2 (2.5) 0.2477 8 (15.4) 1 (1.9) 0.0151
Total charges for hospitalization ($)
Mean (SD) 110,767 (95,592) 55,796 (63,462) <0.0001 76,247 (86,902) 23,535 (28,930) <0.0001
Median 78,498 37,106 47,882 17,583
IQ range 41,640–144,344 9584–71,670 23,713–92,524 8946–29,018
Medicare payments for hospitalization ($)
Mean (SD) 34,268 (31,811) 21,416 (22,449) <0.0001 25,942 (29,122) 10,131 (10,686) <0.0001
Median 25,943 17,555 15,958 7,359
IQ range 14,241–43,816 7,391–24,494 9,523–26,373 5,147–11,385
Source: SEER-Medicare Data, 1991–98.
Percents may not add to 100 because of  rounding.
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are on the lower end of other studies of fungal infec-
tion patients with different underlying conditions
[3,6,19], and the one excess cost estimate among
patients with cancer [3]. Finally, our ﬁnding of Can-
didiasis being  the  most  common  fungal  infection
is consistent with other studies as well [3,5,6].
To our knowledge, this study is the ﬁrst to eval-
uate outcomes of fungal infections among cancer
patients across a wide range of institutions. Most
previous studies have included patients with widely
varying risk factors for fungal infections, and often
were restricted by the use of data from single insti-
tutions [3,5,6,18–21]. Furthermore, our focus on
elderly patients is unique. Finally, our detailed
matching strategy enabled us to control for several
potentially confounding inﬂuences on study
outcomes.
Our study is subject to several limitations. First,
we relied on administrative claims data to assess the
presence of a fungal infection. These data are not
collected speciﬁcally for research purposes and have
known limitations [26]. Furthermore, patients from
SEER registries may not be representative of all US
patients with AML or SCCHN. While SEER data
cover about 14% of all cancer cases, certain groups
are under- or over-represented (e.g., blacks and
“other” races, respectively) [27,28]. Nonetheless,
the linked SEER-Medicare database has proven
extremely useful for understanding oncology treat-
ment patterns and survival for many different can-
cer types, including cancers of the lungs, ovaries,
breast, prostate, colon, rectum, and head and neck,
as well as acute and chronic myeloid leukemias
[22,23,29–39]. While both individual data sources
have their limitations [24], together they have the
advantages of accessibility and broad population-
based coverage over multiple years. In addition, it
should be noted that our samples were relatively
small, and the incidence of serious fungal infection
varied by cancer type. The higher likelihood of
infection observed among AML patients, 3.5% ver-
sus 0.4% for SCCHN, may reﬂect greater immune
system impairment by the underlying malignancy as
well as the relatively higher use of potentially cyto-
toxic chemotherapy regimens. We were unable to
assess how hospital characteristics (e.g., size, cancer
or cancer surgery caseloads, teaching status) might
have inﬂuenced our ﬁndings. This would be an
interesting topic for future research. Finally, out-
comes were evaluated from a limited perspective
(i.e., single payer), and in a speciﬁc population (i.e.,
patients 65 years and older with selected cancers
who were Medicare-eligible and not in HMOs).
Our results therefore apply only to elderly patientsTa
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with AML and SCCHN, and should not be gener-
alized to other age groups or types of cancer.
In summary, the ﬁndings from this study suggest
that elderly cancer patients who experience fungal
infections have substantially prolonged hospitaliza-
tions and greater costs compared with hospitalized
cancer patients without fungal infections. Given this
demonstrated burden, preventive measures for
infection control and timely initiation of treatment
in susceptible populations may yield both clinical
and economic beneﬁts.
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Appendix: ICD-9-CM codes identifying serious fungal infections
Code Description
112.4 Candidiasis––Of lung
112.5 Candidiasis––Disseminated
112.81 Candidiasis––Candidal endocarditis
112.83 Candidiasis––Candidal meningitis
112.85 Candidiasis––Candidal enteritis
114.2 Coccidioidomycosis––Coccidioidal meningitis
114.3 Coccidioidomycosis––Other forms of  progressive coccidioidomycosis
115.01 Histoplasmosis––Infection by histoplasma capsulatum––meningitis
115.02 Histoplasmosis––Infection by histoplasma capsulatum––retinitis
115.03 Histoplasmosis––Infection by histoplasma capsulatum––pericarditis
115.04 Histoplasmosis––Infection by histoplasma capsulatum––endocarditis
115.05 Histoplasmosis––Infection by histoplasma capsulatum––pneumonia
115.11 Histoplasmosis––Infection by histoplasma duboisii––meningitis
115.12 Histoplasmosis––Infection by histoplasma duboisii––retinitis
115.13 Histoplasmosis––Infection by histoplasma duboisii––pericarditis
115.14 Histoplasmosis––Infection by histoplasma duboisii––endocarditis
115.15 Histoplasmosis––Infection by histoplasma duboisii––pneumonia
115.91 Histoplasmosis––Histoplasmosis, unspeciﬁed––meningitis
115.92 Histoplasmosis––Histoplasmosis, unspeciﬁed––retinitis
115.93 Histoplasmosis––Histoplasmosis, unspeciﬁed––pericarditis
115.94 Histoplasmosis––Histoplasmosis, unspeciﬁed––endocarditis
115.95 Histoplasmosis––Histoplasmosis, unspeciﬁed––pneumonia
116.0 Blastomycotic infection––Blastomycosis
116.1 Blastomycotic infection––Paracoccidioidomycosis
116.2 Blastomycotic infection––Lobomycosis
117.3 Other mycoses––Aspergillosis
117.5 Other mycoses––Cryptococcosis
117.6 Other mycoses––Allescheriosis [Petriellidosis]
117.7 Other mycoses––Zygomycosis [Phycomycosis or Mucormycosis]
